桑沃泽提尼布是下一代EGFR外基子20插入抑制剂,转化NSCLC治疗
Manoj Kumbhare1, Dhiraj Gadekar1, Siddhi Chandak1
1SMBT College of Pharmacy, Nandi-hills, Dhamangaon, Igatpuri, Nashik - 422403, India.
概括
桑沃泽提尼布对非小细胞肺癌 (NSCLC) 具有EGFR外因子20插入突变的治疗有前景. 这种下一代EGFR氨酸激酶抑制剂 (TKI) 与现有治疗方法相比,提供了更好的疗效和耐受性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 具有EGFR外因子20插入 (Ex20ins) 突变,对当前的EGFRTKI反应不佳.
- 有限的治疗选择存在,化疗是主要治疗方法.
- 像阿米万他马布和mobocertinib这样的新药已经显示出改善,但面临耐受性和中枢神经系统透挑战.
研究的目的:
- 评估Sunvozertinib (DZD9008),一种下一代EGFR TKI,用于治疗具有Ex20ins突变的NSCLC.
- 评估Sunvozertinib的疗效,安全性和中枢神经系统活性.
- 解决现有疗法的局限性,包括耐药性,耐受性和中枢神经系统透性.
主要方法:
- 临床前研究评估EGFR Ex20ins变体和野生型EGFR的抑制.
- 在动物模型中评估中枢神经系统活动.
- 早期临床试验 (例如,WU-KONG系列) 的分析,包括客观反应率 (ORR) 和不良事件.
主要成果:
- 桑沃泽提尼布证明了各种EGFR Ex20ins突变的强有力的抑制,同时节省了野生型EGFR.
- 在临床前模型中观察到有前途的中枢神经系统活动.
- 在早期的临床试验中,预先治疗的患者的ORR为44-60%,在未经治疗的队列中,ORR为44-60%.
- 与其他药物相比,可管理的耐受性与较轻的不良事件 (腹,皮疹,口炎).
结论:
- 桑沃泽提尼布是一种潜在的下一代EGFR TKI,用于具有Ex20ins突变的NSCLC.
- 它提供了有利的安全效益平衡,提高了耐受性和中枢神经系统活动.
- 需要进一步的临床开发,以确定其在NSCLC治疗中的作用.
更多相关视频
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
879
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
00:59Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
506
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K